Cue Biopharma lines up $30M to fund pipeline and Ascendant-221

Cue Biopharma (NASDAQ: CUE) announced a private placement to raise approximately $30 million in gross proceeds through pre-funded warrants and accompanying warrants. The proceeds are intended to advance the company’s clinical pipeline, including the acquisition and development of Ascendant-221, and for general corporate purposes. This news led to a positive market reaction, with CUE’s stock gaining 14.25%.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin